Oncolytic Virus Cancer Therapy Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore our latest breakthroughs in Oncolytic Virus Cancer Therapy Research. Learn more about our innovative pipeline today! @ Oncolytic Virus Cancer Therapy Pipeline Outlook
Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report
In June 2025, Replimune Inc. conducted a study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC.
DelveInsight's Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment.
The leading Oncolytic Virus Cancer Therapy Companies such as Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
Promising Oncolytic Virus Cancer Therapy Pipeline Therapies such as Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others.
Stay informed about the cutting-edge advancements in Oncolytic Virus Cancer Therapy treatments. Download for updates and be a part of the revolution in Oncology Care @ Oncolytic Virus Cancer Therapy Clinical Trials Assessment
Oncolytic Virus Cancer Therapy Emerging Drugs Profile
Olvi-Vec: Genelux Corporation
Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. Currently the product is in Phase III stage of development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer
CAN-2409: Candel Therapeutics
CAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. Currently the product is in Phase III stage of development for the treatment of Prostrate Cancer.
CG0070: CG Oncology
CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor's cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body's own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure. Currently the product is in Phase III stage of development for the treatment of Non Muscular Invasive Bladder Cancer.
Pelareorep: Oncolytics Biotech
Pelareorep, is an investigational drug being developed by Oncolytics Biotech. It is an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Currently the drug is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Metastatic Breast Cancer.
ParvOryx: Oryx GmbH
ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. H-1PV acts at relatively low multiplicities of infection. The virus exerts both cytotoxic and oncolytic (replication) effects. The cytotoxic effect is predominantly mediated by the non-structural protein (NS1), resulting in cell transcription dysregulation, cell cycle arrest, cell replication shut off, and activation of cellular stress response and induction of cell death. In addition, viral oncolysis induces a strong tumor-specific immune response leading to the recognition and elimination of minimal residual disease (bystander effect). ParvOryx is the smallest of all oncolytic viruses and is able to cross the blood brain barrier. Unlike other natural or modified oncolytic viruses currently under investigation, ParvOryx does not affect normal cells and is not pathogenic to humans. Currently the product is in Phase II stage of development for the treatment of pancreatic cancer.
SND005: Jiangsu Sinorda Biomedicine
SND005 Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. Initially, some tumor cells were specifically infected and destroyed by oncolytic viruses. Subsequently, the oncolytic virus replicates and proliferates in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response. Among the new oncolytic virus drugs currently underway, SND005 is the only wild-type virus without genetic modification. It has a 14 - year history of clinical use. In a trial of 540 patients with melanoma, more than 44% of the patients benefited. In the safety and tolerability study of 190 patients, no serious adverse events were found, and the most common adverse event was low-grade fever. The clinical data and observations after the overseas market show that the survival rate of patients is increased by 4- 5 times, and it has excellent performance in stage II melanoma patients.
VCN-01: VCN Biosciences
VCN-01 is an innovativeconditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase. Expression of hyaluronidase from VCN-01 facilitates virus penetration and decreases intratumorfluid pressure, enhancing antibodyup-take. In addition, VCN-01 capsid has been modified to allow the virus to partially evade liver tropism and target selectively the tumor after intravenous administration. Currently the product is in Phase I stage of development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck.
The Oncolytic Virus Cancer Therapy Pipeline Report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment.
Oncolytic Virus Cancer Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market.
Learn more about Oncolytic Virus Cancer Therapy Drugs opportunities in our groundbreaking Oncolytic Virus Cancer Therapy research and development projects @ Oncolytic Virus Cancer Therapy Unmet Needs
Oncolytic Virus Cancer Therapy Companies
Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intranasal
Intravenous
Oral
Oral/Intravenous
Parenteral
Subcutaneous
Subcutaneous/Intramuscular
Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types such as
Oncolytic Virus
Discover the latest advancements in Oncolytic Virus Cancer Therapy treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Oncolytic Virus Cancer Therapy Market Drivers and Barriers, and Future Perspectives
Scope of the Oncolytic Virus Cancer Therapy Pipeline Report
Coverage- Global
Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others.
Oncolytic Virus Cancer Therapy Pipeline Therapies- Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others.
Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Oncolytic Virus Cancer Therapy Pipeline on our website @ Oncolytic Virus Cancer Therapy Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Oncolytic Virus Cancer Therapy: Overview
Pipeline Therapeutics
Therapeutic Assessment
Oncolytic Virus Cancer Therapy– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Olvi-Vec: Genelux Corporation
Mid Stage Products (Phase II)
SND005: Jiangsu Sinorda Biomedicine
Early Stage Products (Phase I/II)
AloCelyvir: Orgenesis
Early Stage Products (Phase I)
VCN-01: VCN Biosciences
Preclinical and Discovery Stage Products
SynOV 1.3: Beijing Syngentech
Inactive Products
Oncolytic Virus Cancer Therapy Key Companies
Oncolytic Virus Cancer Therapy Key Products
Oncolytic Virus Cancer Therapy- Unmet Needs
Oncolytic Virus Cancer Therapy- Market Drivers and Barriers
Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion
Oncolytic Virus Cancer Therapy Analyst Views
Oncolytic Virus Cancer Therapy Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
37 minutes ago
- Globe and Mail
Why Tesla Stock Jumped Today
Key Points Tesla inked a $16.5 billion chip manufacturing deal with Samsung to produce its next-generation chips. The chips will be produced in Texas and are designed to enable advanced artificial intelligence (AI) features for Tesla's vehicles and personal robotics. Tesla faces major near-term challenges, as sales have slipped globally. These 10 stocks could mint the next wave of millionaires › Shares of Tesla (NASDAQ: TSLA) climbed higher on Monday. The electric vehicle (EV) maker's stock gained 3% as of market close, but had jumped as much as 4.6% earlier in the day. The spike comes as the S&P 500 (SNPINDEX: ^GSPC) was flat and the Nasdaq Composite (NASDAQINDEX: ^IXIC) rose 0.3%. Tesla signed a major deal with Samsung to manufacture its next-generation AI6 chips. Tesla inked a massive deal with Samsung Tesla and Samsung's $16.5 billion deal will see the South Korean electronics giant manufacture Tesla's chips, producing them in its new factory in Texas. CEO Elon Musk said on X that, along with producing the chips, "Samsung agreed to allow Tesla to assist in maximizing manufacturing efficiency," adding that, "The $16.5B number is just the bare minimum. Actual output is likely to be several times higher." While it will be years before the first AI6 chips -- designed to enable artificial intelligence (AI) inference for Tesla's vehicles and personal robots -- roll off the line, the news was enough to send Tesla shares higher. It's a critical time for Tesla The deal will help Tesla bring its vision for the future closer to reality, but it's still a long road. In the meantime, Tesla is struggling. The company faces increased competition from Chinese EV makers like BYD as it sees its sales sharply decline around the globe. Musk's own foray into politics has done significant damage to Tesla's brand. The next year will be very telling whether Tesla can find its footing once again. I have my doubts, and I continue to think the stock is significantly overpriced. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $449,961!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $40,603!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $636,628!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon. *Stock Advisor returns as of July 28, 2025
Globe and Mail
3 hours ago
- Globe and Mail
Bakkt Announces Pricing of $75 Million Public Offering
Bakkt Holdings, Inc. ('Bakkt' or the 'Company') (NYSE: BKKT) today announced the pricing of its previously announced underwritten public offering of 6,753,627 shares of Class A common stock and pre-funded warrants to purchase up to 746,373 shares of Class A common stock at a public offering price of $10.00 per share and public offering price of $9.9999 per pre-funded warrant, which represents the per share public offering price of each share of Class A common stock less the $0.0001 per share exercise price for each pre-funded warrant. The offering is expected to close on or around July 30, 2025, subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses, are expected to be approximately $75 million. Bakkt intends to use the net proceeds from the offering to purchase Bitcoin and other digital assets in accordance with its investment policy, for working capital and for general corporate purposes. Bakkt has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of Class A common stock and/or pre-funded warrants at the public offering price, less underwriting discounts and commissions. Clear Street LLC and Cohen & Company Capital Markets, a division of Cohen & Company Securities, LLC, are acting as joint book-running managers of the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-288361) declared effective by the Securities and Exchange Commission (the 'SEC') on July 3, 2025. A final prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission, together with an accompanying base prospectus. The securities may be offered only by means of a written prospectus forming a part of the effective registration statement. Copies of the final prospectus supplement relating to the offering, together with the accompanying base prospectus, may be obtained, when available, from the SEC's website at from Clear Street LLC, Attention: Syndicate, 4 World Trade Center 150 Greenwich St Floor 45 New York, NY 10007, or by email at syndicate@ and from Cohen & Company Capital Markets, Attention: Prospectus Department, 3 Columbus Cir, New York, NY 10019, or by email at capitalmarkets@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. Bakkt will not, and has been advised by the joint book-running managers that they and their affiliates will not, sell any of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Bakkt Founded in 2018, Bakkt builds solutions that enable our clients to grow with the crypto economy. Through institutional-grade trading and onramp capabilities, our clients leverage technology that's built for sustainable, long-term involvement in crypto. Bakkt is headquartered in Alpharetta, GA. For more information, visit: | @Bakkt | LinkedIn Bakkt-C Cautionary Note Regarding Forward-Looking Statements This release contains 'forward-looking statements' within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities and Exchange Act of 1934, as amended. Such statements include, but are not limited to, statements regarding the offering. Forward-looking statements can be identified by words such as 'will,' 'likely,' 'expect,' 'continue,' 'anticipate,' 'estimate,' 'believe,' 'intend,' 'plan,' 'projection,' 'outlook,' 'grow,' 'progress,' 'potential' or the negative of such terms or other variations thereof and words and terms of similar substance used in connection with any discussion of future plans, actions, or events identify forward-looking statements. However, the absence of these words does not mean that the statements are not forward-looking. Such forward-looking statements are based upon the current beliefs and expectations of the Company's management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and beyond the Company's control. Actual results and the timing of events may differ materially from the results anticipated in such forward-looking statements as a result of the following factors, among others: the Company's ability to continue as a going concern; the Company's ability to grow and manage growth profitably; the possibility that the Company may be unable to obtain the applicable regulatory approvals to execute on the cooperation agreement with Distributed Technologies Research Global Ltd. ('DTR'); finalizing the proposed commercial agreement with DTR, including whether such agreement will be executed on terms favorable to the Company or if at all, or be completed on the expected timeline, and whether the Company will be able to successfully integrate its operations with those of DTR, including its infrastructure, and achieve the expected benefits therefrom; the regulatory environment for crypto currencies and digital stablecoin payments; changes in the Company's business strategy, including its adoption of its updated investment policy ('Investment Policy') as described in the Company's Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the 'SEC') on June 10, 2025 (the 'June 10, 2025 8-K'); the price of digital assets, including Bitcoin; risks associated with owning digital assets, including Bitcoin, including price volatility, limited liquidity and trading volumes, relative anonymity, potential widespread susceptibility to market abuse and manipulation, compliance and internal control failures at exchanges and other risks inherent in its entirely electronic, virtual, form and decentralized network; the fluctuation of the Company's operating results, including because the Company may be required to account for its digital assets at fair value; the Company's ability to time the price of its purchase of digital assets pursuant to its strategy; the impact of the market value of digital assets on the Company's ability to satisfy its financial obligations, including any debt financings; unrealized fair value gains on its digital asset holdings subjecting the Company to the corporate alternative minimum tax; legal, commercial, regulatory and technical uncertainty regarding digital assets and enhanced regulatory oversight of companies holding digital assets including the possibility that regulators reclassify any digital assets the Company holds, including Bitcoin, as a security causing the Company to be in violation of securities laws and be classified as an 'investment company' under the Investment Company Act of 1940; competition by other Bitcoin treasury companies and the availability of spot-traded products for Bitcoin; enhanced regulatory oversight as a result of the Company's Investment Policy; the possibility of experiencing greater fraud, security failures or operational problems on digital asset trading venues compared to trading venues for more established asset classes, and any malfunction, breakdown or abandonment of the underlying blockchain protocols, or other technological difficulties, may prevent access to or use of such digital assets; the concentration of the Company's expected digital asset holdings relative to non-digital assets; the inability to use the Company's digital asset holdings as a source of liquidity to the same extent as cash and cash equivalents, due to, for example, risks associated with digital assets and other risks inherent to its entirely electronic, virtual form and decentralized network; the Company or a third-party service provider experiencing a security breach or cyber-attack where unauthorized parties obtain access to its digital assets; the loss of access to or theft or data loss of the Company's digital assets, which could be unrecoverable due to the immutable nature of blockchain transactions; if the Company elects to hold its digital assets through a third-party custodian, the loss of direct control over its digital assets and dependence on the custodian's security practices and operational integrity which may lead to the loss of its digital assets as a result of the insolvency of the custodian, theft by employees or insiders of the custodian or if the custodian's security measures are comprised, including as a result of a cyber-attack; the Company not being subject to the legal and regulatory protections applicable to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisers; the non-performance, breach of contract or other violations by counterparties assisting the Company in effecting its Investment Policy; the Company's future capital requirements and sources and uses of cash, including funds to satisfy its liquidity needs and continued access to the line of credit with Intercontinental Exchange Holdings, Inc.; changes in the market in which the Company competes, including with respect to its competitive landscape, technology evolution or changes in applicable laws or regulations; changes in the markets that the Company targets; volatility and disruptions in the crypto, digital payments and stablecoin markets that subject the Company to additional risks, including the risk that banks may not provide banking services to the Company and market sentiments regarding crypto currencies, digital payments and stablecoins; the possibility that the Company may be adversely affected by other macroeconomic, geopolitical, business, and/or competitive factors; the Company's ability to launch new services and products, including with its expected commercial partners, or to profitably expand into new markets and services; the Company's ability to execute its growth strategies, including identifying and executing acquisitions and divestitures and the Company's initiatives to add new clients; the Company's ability to reach definitive agreements with its expected commercial counterparties; the Company's ability to successfully complete a strategic transaction of the Loyalty business; the Company's failure to comply with extensive government regulations, oversight, licensure and appraisals; uncertain and evolving regulatory regime governing blockchain technologies, stablecoins, digital payments and crypto; the Company's ability to establish and maintain effective internal controls and procedures; the exposure to any liability, protracted and costly litigation or reputational damage relating to the Company's data security; the impact of any goodwill or other intangible assets impairments on the Company's operating results; the Company's ability to maintain the listing of its securities on the New York Stock Exchange; and other risks and uncertainties indicated in the Company's filings with the SEC, including its most recent Annual Report on Form 10-K for the year ended December 31, 2024 and its most recent quarterly report on Form 10-Q for the quarter ended March 31, 2025, and the risks regarding the Company's adoption of its Investment Policy set forth in Exhibit 99.1 to the June 10, 2025 8-K. You are cautioned not to place undue reliance on such forward-looking statements. Such forward-looking statements relate only to events as of the date on which such statements are made and are based on information available to us as of the date of this release.
Globe and Mail
4 hours ago
- Globe and Mail
Procter & Gamble replaces CEO Jon Moeller with long-time executive Shailesh Jejurikar
Procter & Gamble PG-N CEO Jon Moeller is stepping away from the top job after four years in the role, and the consumer goods giant said he would be succeeded by chief operating officer Shailesh Jejurikar. Moeller will become executive chairman and 'provide advice and counsel to the CEO on company matters,' P&G said in a statement on Monday, a day before it was scheduled to report its quarterly results. The company did not disclose the reason for the change in leadership in its statement, but P&G chief communications officer Damon Jones told Reuters Moeller's departure was part of a planned and orderly transition made by the board. There were no health concerns leading to Moeller's departure, he said. The Cincinnati-based company has a history of relatively short CEO terms, dating back to the mid-1990s. Moeller's predecessor David Taylor was CEO for six years, two of which were during the COVID pandemic when consumer goods companies faced product shortages and supply chain snags. Taylor then served as executive chairman of the board. Procter & Gamble looks to raise prices as tariffs hit costs, force forecast cuts Under Moeller, the company navigated a postpandemic sales boom, as well as rising expenses and sticky inflation. P&G shares gained roughly 13 per cent during his four-year tenure, in line with the S&P 500 index. The company, which makes Pampers diapers and Head & Shoulders shampoo, in April warned of higher product prices due to an increase in input costs from the trade war at a time of weakening consumer spending. Its stock is down about 6 per cent so far this year. In June, the company said it would cut 7,000 jobs over the next two years and exit some product categories and brands in certain markets, including some potential divestitures, as part of a broader two-year restructuring plan. 'It might not mean much to the outlook since they're promoting from within,' said Brian Jacobsen, chief economist at Annex Wealth Management, which holds P&G shares. 'This could be more like the passing of the baton in a long race rather than shaking things up.' Jejurikar's appointment, effective Jan. 1, 2026, keeps up with P&G's preference for naming internal candidates for the top job. Moeller had also risen through the ranks before becoming the COO and then CEO of the company. The board has nominated Jejurikar as a director at the annual shareholder meeting in October, 2025. Jejurikar has held roles across multiple P&G businesses, including Health & Beauty Care and P&G Professional. Prior to his current role, he was the head of P&G's Fabric & Home Care, which includes brands such as Tide, Ariel and Downy.
